Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in pat... Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. Show more
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire AUSTIN, Texas, Sept. 23, 2024...
Aileron Therapeutics to Present at the 8th Annual IPF Summit PR Newswire AUSTIN, Texas, Aug. 19, 2024 AUSTIN, Texas, Aug. 19, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:...
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights PR Newswire AUSTIN, Texas, Aug. 14, 2024 Announced positive data from Cohort 1 of the ongoing Phase 1b...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.9 | 32.1428571429 | 2.8 | 3.83 | 2.65 | 284984 | 3.15032746 | CS |
4 | 1.27 | 52.2633744856 | 2.43 | 3.83 | 2.2566 | 96869 | 3.05981847 | CS |
12 | 0.87 | 30.74204947 | 2.83 | 3.83 | 1.61 | 72560 | 2.77705795 | CS |
26 | -2.33 | -38.64013267 | 6.03 | 7.42 | 1.61 | 91436 | 3.75452136 | CS |
52 | 2.17 | 141.830065359 | 1.53 | 7.42 | 1.01 | 85156 | 3.65278553 | CS |
156 | -17.5 | -82.5471698113 | 21.2 | 22.4 | 1.01 | 255876 | 7.18874516 | CS |
260 | -14.998 | -80.2117873569 | 18.698 | 49.4 | 1.01 | 609297 | 22.93035815 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.